In vivo imaging of baboon and human dopamine transporters by positron emission tomography using [11C]WIN 35,428
- 12 October 1993
- Vol. 15 (2) , 130-142
- https://doi.org/10.1002/syn.890150205
Abstract
[11C]WIN 35,428 was evaluated as a specific in vivo radioligand for the dopamine transporter site by PET scanning in nonhuman primates and humans. In studies with a baboon (Papio anubis), [11C]WIN 35,428 accumulated in brain regions containing dopamine transporters, i.e., the striata. This accumulation was partially blocked by prior administration of (-)cocaine (4 mg/kg, i.v.). Placement of a unilateral lesion of dopamine-containing nerve terminals with MPTP resulted in a unilateral reduction in [11C]WIN 35,428 accumulation in the striatum on the side of the lesion. Imaging of D2 dopamine receptors with [11C]NMSP in the same MPTP-treated animals showed much less reduction in the postsynaptic D2 dopamine receptors as compared to the much larger reduction in the dopamine transporters labeled with [11C]WIN 35,428. A total of ten normal human volunteers (five males and five females) with ages ranging from 19 to 81 years were studied. The caudate/cerebellar and putamen/cerebellar ratios ranged from 4.4 to 5.7 90 min after injection of the tracer. Preliminary kinetic modeling with arterial plasma sampling resulted in an average binding potential (k3/k4) of 4.98 in the caudate nucleus and 5.13 in putamen. To demonstrate in vivo blockade with dopamine reuptake inhibitors, two subjects received prior oral doses of 6 mg mazindol. Subject 5 had significant reductions of 29% in the caudate/cerebellar ratio at 90 min, 35% in the putamen/cerebellar ratio at 90 min, 45% in the caudate k3/k4 ratio from 6.7 to 3.7, and 46% in the putamen k3/k4 from 4.7 to 2.5. Subject 8 had significant reductions of 20% in both the caudate/cerebellar ratio and the putamen/cerebellar ratio at 90 min. During the human PET studies, a number of neuropsychological tests and physiological measurements were performed. No significant changes were found after administration of the [11C]WIN 35,428 alone. Taken together, these data indicate that [11C]WIN 35,428 is a promising radioligand for future studies of neuropsychiatric disorders that involve the dopamine transporter site.Keywords
This publication has 34 references indexed in Scilit:
- Synthesis of a radiotracer for studying dopamine uptake sites in vivo using PET: 2β‐carbomethoxy‐3β‐(4‐fluorophenyl)‐[N‐11C‐methyl]tropane ([11C]CFT or [11C]WIN‐35,428)Journal of Labelled Compounds and Radiopharmaceuticals, 1993
- Dopamine transporter imaging with novel, selective cocaine analogsNeuroReport, 1992
- In vivo imaging of dopamine reuptake sites in the primate brain using single photon emission computed tomography (SPECT) and iodine‐123 labeled RTI‐55Synapse, 1992
- Normal aging of the nervous systemAnnals of Neurology, 1991
- Nigrostriatal function in humans studied with positron emission tomographyAnnals of Neurology, 1989
- Kinetic Analysis of Central [11C]Raclopride Binding to D2-Dopamine Receptors Studied by PET—A Comparison to the Equilibrium AnalysisJournal of Cerebral Blood Flow & Metabolism, 1989
- Monoamine re-uptake sites in the human brain evaluatedin vivoby means of11C-nomifensine and positron emission tomography: the effects of age and Parkinson's diseaseActa Neurologica Scandinavica, 1988
- In vivo binding of [18F]GBR 13119 to the brain dopamine uptake systemLife Sciences, 1988
- “In vivo” visualization by positron emission tomography of the progressive striatal dopamine receptor damage occuring in MPTP-intoxicated non-human primatesLife Sciences, 1986
- Quantification of Neuroreceptors in the Living Human Brain. II. Inhibition Studies of Receptor Density and AffinityJournal of Cerebral Blood Flow & Metabolism, 1986